Treatment Outcomes of Remdesivir in COVID-19 Patients
DOI:
https://doi.org/10.51253/pafmj.v75i2.10327Keywords:
COVID-19, Remdesivir, SARS-CoV-2, Safety, Treatment outcomeAbstract
Objective: To evaluate effectiveness of Remdesivir in COVID-19 patients in terms of length of hospital stay, duration of oxygen dependency, and mortality.
Study Design: Quasi-experimental study.
Place and Duration of Study: Department of Medicine, Combined Military Hospital, Bahawalpur Pakistan, from Nov 2021 to Apr 2022.
Methodology: We included 170 patients diagnosed with COVID-19 and recorded their clinical characteristics in addition to outcomes related towards oxygen dependence, death, and hospital stay duration on a self-designed data collection tool which was administered by the researchers. The data was analyzed, and statistical correlations were determined.
Results: Our total sample size of 170 patients, comprised of 91(53.5%) males and 79(46.5%) females with an average age of 53.95±14.09 years. We noted mild disease to be present in 17.6 % of patients, moderate in 65.9 %, and severe in 16.5 % while 65 (38.2%) patients were oxygen-dependent at the time of admission. Fever was the most frequent complaint experienced by 84.7% of patients. Remdesivir was administered to 90(52.9%) patients, among which 65 recovered early with a hospital stay of less than a week while 20(23.3%) patients had prolonged stay due to oxygen dependency, other complications (10, 11.1%) or comorbidities (11, 12.2 %) respectively (p-value=0.000) while the rate of mortality was also significantly reduced in patients who received Remdesivir (4.44 %) compared to those who did not (17.5 %) (p-value<0.001).
Conclusion: Remdesivir significantly decreased the duration of hospital stay, oxygen dependency, and rate of mortality without causing any adverse effects.
Downloads
References
Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020; 323(13): 1239-1242.
https://doi.org/10.1001/jama.2020.2648
Noor AU, Maqbool F, Bhatti ZA, et al. Epidemiology of COVID-19 pandemic: recovery and mortality ratio around the globe. Pak J Med Sci 2020; 36(COVID19-S4): S79-84.
https://doi.org/10.12669/pjms.36.COVID19-S4.2696
Abid K, Bari YA, Younas M, et al. Progress of COVID-19 epidemic in Pakistan. Asia Pac J Public Health 2020; 32(4): 154-156. https://doi.org/10.1177/1010539520927259
Pollard CA, Morran MP, Nestor-Kalinoski AL, et al. The COVID-19 pandemic: A global health crisis. Physiol Genomics 2020; 52(11): 549-557.
https://doi.org/10.1152/physiolgenomics.00089.2020
Morse JS, Lalonde T, Xu S, et al. Learning from the past: possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019-nCoV. ChemBioChem 2020; 21(5): 730-738.
https://doi.org/10.1002/cbic.202000047
Li Z, Wang X, Cao D, et al. Rapid review for the anti-coronavirus effect of remdesivir. Drug Discov Ther 2020; 14(2): 73-76. https://doi.org/10.5582/ddt.2020.01015
Davies M, Osborne V, Lane S, et al. Remdesivir in treatment of COVID-19: a systematic benefit–risk assessment. Drug Saf 2020; 43(7): 645-656.
https://doi.org/10.1007/s40264-020-00952-1
Department of Health and Family Welfare. Clinical management guidelines for Covid19. Minist NHSRC 2020.
Rezagholizadeh A, Khiali S, Sarbakhsh P, et al. Remdesivir for treatment of COVID-19; an updated systematic review and meta-analysis. Eur J Pharmacol 2021; 897: 173926.
https://doi.org/10.1016/j.ejphar.2021.173926
WHO Solidarity Trial Consortium. Repurposed antiviral drugs for COVID-19 — interim WHO Solidarity Trial results. N Engl J Med 2021; 384(6): 497-511.
https://doi.org/10.1056/NEJMoa2023184
Dolin R, Hirsch MS. Remdesivir — an important first step. N Engl J Med 2020; 383(19): 1886-1887.
https://doi.org/10.1056/NEJMe2024928
Abd-Elsalam S, Salama M, Soliman S, et al. Remdesivir efficacy in COVID-19 treatment: a randomized controlled trial. Am J Trop Med Hyg 2022; 106(3): 886-890.
https://doi.org/10.4269/ajtmh.21-0876
Malik MI, Zafar SAF, Malik M, et al. The utility of remdesivir in SARS-CoV-2: a single tertiary care center experience from a developing country. Explor Res Clin Soc Pharm 2022; 5: 100107.
https://doi.org/10.1016/j.rcsop.2021.100107
Durrani M, Haq IU, Kalsoom U, et al. Chest x-rays findings in covid 19 patients at a university teaching hospital—a descriptive study. Pak J Med Sci 2020; 36(COVID19-S4): S22-26.
https://doi.org/10.12669/pjms.36.COVID19-S4.2773
Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med 2020; 8(4): e21.
https://doi.org/10.1016/S2213-2600(20)30116-8
Guan W, Ni Z, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382(18): 1708-1720. https://doi.org/10.1056/NEJMoa2002032
Gupte V, Hegde R, Sawant S, et al. Safety and clinical outcomes of remdesivir in hospitalized COVID-19 patients: a retrospective analysis of active surveillance database. BMC Infect Dis 2022; 22(1): 1-8.
https://doi.org/10.1186/s12879-022-07073-3
Thiruchelvam K, Kow CS, Hadi MA, et al. The use of remdesivir for the management of patients with moderate-to-severe COVID-19: a systematic review. Expert Rev Anti Infect Ther 2022; 20(2): 211-229.
https://doi.org/10.1080/14787210.2021.2013807
Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2020; 395(10236): 1569-1578.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Hira Iqbal; Syed Waqar Abbas, Ahmar Rasheed, M Faheem ur Rehman, Farooq ., Umar Iqbal, Hafiz Asad Saeed
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
